professional corporation or professional association; (2) provides services and related supplies of a type rendered by TRICARE individual professional providers or diagnostic technical services; (3) is approved for Medicare payment or, when Medicare approval status is not required, is accredited by a qualified accreditation organization; and (4) has entered into a participation agreement approved by the Director, DHA or a designee.

The collected information will be used by TRICARE contractors to process claims and verify authorized provider status. Verification involves collecting and reviewing copies of the provider's licenses, certificates, accreditation documents, etc. If the criteria are met, the provider is granted TRICARE authorization status. The documentation and information are collected when: (1) A provider requests permission to become a TRICARE-authorized provider; (2) a claim is filed for care received from a provider who is not listed on the contractors' computer listing of authorized providers; or (3) when a former TRICARE-authorized provider requests reinstatement. The contractors develop the forms used to gather information based on TRICARE conditions for participation listed above. Without the collection of this information, contractors cannot determine if the provider meets TRICARE-authorization requirements for corporate services providers. If the contractor is unable to verify that a provider meets these authorization requirements, the contractor may not reimburse either the provider or the beneficiary for the provider's health care services. To reduce the reporting burden to a minimum, TRICARE has carefully selected the information requested from respondents. Only that information which has been deemed absolutely essential is being requested. If necessary, contractors may verify credentials with Medicare, JCAHO and other national organizations by telephone. TRICARE is also participating with Medicare in the development of a National Provider System which will eliminate duplication of provider certification data collection among Federal government agencies. TRICARE contractors are required to maintain a computer listing of all providers that have submitted the appropriate authorization information and documentation. To avoid duplicate inquires, the contractors must search the computer provider listing before requesting documentation from providers. Since the providers affected

by this information collection generally have not previously been eligible to be authorized providers, TRICARE contractors will have no information on file. The providers will have to submit the information requested on the data collection form (Application for **TRICARE-Providers Status: Corporate** Services Provider) in order to obtain provider authorization status under TRICARE. The information will usually be collected from each respondent only once. It is estimated that there will be approximately 300 applicants per year. TRICARE will request the provider authorization documentation and information when the provider asks to become TRICARE-authorized or when a claim is filed for a new provider's services. If after a provider has been authorized by a contractor, no claims are filed during two-year period of time, the provider's information will be placed in the inactive file. To reactivate a file, the provider must verify that the information is still correct, or supply new or changed information. The total annual reporting burden is estimated to be approximately 100 hours (approximately 300 respondents with 20 minutes to complete the form).

Dated: January 7, 2014.

Aaron Siegel, Alternate OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. 2014–00296 Filed 1–10–14; 8:45 am] BILLING CODE 5001–06–P

#### DEPARTMENT OF DEFENSE

#### Department of the Army

## Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Anti-Filovirus Therapeutics

**AGENCY:** Department of the Army, DoD. **ACTION:** Notice.

SUMMARY: Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/ 761,942, entitled "Anti-Filovirus Therapeutics," filed on February 7, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012.

**FOR FURTHER INFORMATION CONTACT:** For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For

licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034.

**SUPPLEMENTARY INFORMATION:** The invention relates to an antisense oligonucleotide directed to a mRNA encoding a mammalian Niemann-Pick C1 (NPC1) receptor, and combinations thereof and compositions comprising such are provided. Also provided are methods of treating or reducing filovirus infection of a subject.

# Brenda S. Bowen,

Army Federal Register Liaison Officer. [FR Doc. 2014–00290 Filed 1–10–14; 8:45 am] BILLING CODE 3710–08–P

## DEPARTMENT OF DEFENSE

#### **Department of the Army**

Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Imidazenil, or a Combination of Imidazenil and [+]-Huperzine A and/or [-]-Huperzine A for Protection Against and/or Treatment of Seizure/Status Epilepticus and Neuropathology Following Nerve Agent or Organophosphate Exposure, Compositions and Kits

**AGENCY:** Department of the Army, DoD. **ACTION:** Notice.

**SUMMARY:** Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/ 726,753, entitled "Imidazenil, or a Combination of Imidazenil and [+]-Huperzine A and/or [-]-Huperzine A for Protection Against and/or Treatment of Seizure/Status Epilepticus and Neuropathology Following Nerve Agent or Organophosphate Exposure, Compositions and Kits," filed on November 15, 2012. The United States Government, as represented by the Secretary of the Army, has rights to this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034. SUPPLEMENTARY INFORMATION: The invention relates to methods, compositions and kits for use in protection against and/or treatment of chemical warfare nerve agent (CWNA) and/or organophosphate (OP) pesticide/ insecticide exposure. In particular, the present invention relates to methods, compositions and kits for treating, preventing, inhibiting or reducing a seizure, status epilepticus, neuropathogenesis, or a neuropathology caused by exposure to a CWNA or an OP pesticide/insecticide using (a) imidazenil, (b) a combination treatment comprising imidazenil and [+]-Huperzine A, (c) a combination treatment comprising imidazenil and [-]-Huperzine A, or (d) a combination treatment comprising imidazenil, [+]-Huperzine A and [-]-Huperzine A.

## Brenda S. Bowen,

Army Federal Register Liaison Officer. [FR Doc. 2014–00286 Filed 1–10–14; 8:45 am] BILLING CODE 3710–08–P

# DEPARTMENT OF DEFENSE

## Department of the Army

Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Measurements of the Inhibition of Synaptic Activity (MISA) To Detect, Study and Evaluate All Active Botulinum Neurotoxin Serotypes

**AGENCY:** Department of the Army, DoD. **ACTION:** Notice.

**SUMMARY:** Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/851,599, entitled "Measurements of the Inhibition of Synaptic Activity (MISA) to Detect, Study and Evaluate All Active Botulinum Neurotoxin Serotypes," filed on March 8, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012.

**FOR FURTHER INFORMATION CONTACT:** For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034.

**SUPPLEMENTARY INFORMATION:** The invention relates to measurements of spontaneous or evoked electrical activity in networked populations of primary neurons or stem cell-derived neurons as a rapid, sensitive assay for the presence of functional botulinum neurotoxin (BoNT) in various matrices.

#### Brenda S. Bowen,

Army Federal Register Liaison Officer. [FR Doc. 2014–00283 Filed 1–10–14; 8:45 am] BILLING CODE 3710–08–P

# **DEPARTMENT OF DEFENSE**

# Department of the Army

Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Low Fat, High Protein, High Carbohydrate Complete Enteral Nutritional Compositions for Treatment of Burn Patients

**AGENCY:** Department of the Army, DoD. **ACTION:** Notice.

**SUMMARY:** Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/733,938, entitled "Low Fat, High Protein, High Carbohydrate Complete Enteral Nutritional Compositions for Treatment of Burn Patients," filed on December 6, 2012. The United States Government, as represented by the Secretary of the Army, has rights to this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012.

**FOR FURTHER INFORMATION CONTACT:** For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034.

**SUPPLEMENTARY INFORMATION:** The invention relates to low fat, high protein, high carbohydrate enteral nutritional formulations for use in providing the complete nutritional needs of subjects with severe burn, methods of providing nutritional support to burn patients using these formulations, and methods of making the same. These complete enteral nutritional formulations are polymeric, concentrated, and do not contain added arginine. In addition, these enteral nutritional formulations are homogeneous solutions that flow through tubing well.

## Brenda S. Bowen,

Army Federal Register Liaison Officer. [FR Doc. 2014–00287 Filed 1–10–14; 8:45 am] BILLING CODE 3710–08–P

## DEPARTMENT OF DEFENSE

#### Department of the Army

Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Contact Pathway and Tissue Kallikrein Inhibitors Can Prevent/Reduce Leakage Caused by Hantavirus

**AGENCY:** Department of the Army, DoD. **ACTION:** Notice.

**SUMMARY:** Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/851,573, entitled "Contact Pathway and Tissue Kallikrein Inhibitors can Prevent/Reduce Leakage Caused by Hantavirus," filed on March 15, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034.

**SUPPLEMENTARY INFORMATION:** The invention relates to treatment of vascular leakage symptoms infected with the Hantavirus using drugs that are already FDA approved.

# Brenda S. Bowen,

Army Federal Register Liaison Officer. [FR Doc. 2014–00285 Filed 1–10–14; 8:45 am] BILLING CODE 3710–08–P

# DEPARTMENT OF DEFENSE

# Defense Acquisition Regulations System

[Docket Number DARS-2013-0038]

# Submission for OMB Review; Comment Request

ACTION: Notice.